CSBR Stock Analysis: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$5.84
0.10 (1.74%)
▲
5d:
-2.01%
30d:
-1.93%
90d:
-18.33%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Mar 17, 2026
0d
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CSBR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: CSBR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $5.84, which is considered slightly low relative to its 30-day fair value range of $5.78 to $6.07. The stock's valuation (Forward PE: 58.4) is in line with its historical norms (54.9). At these levels, the market is pricing in 2.1% annual earnings growth.
Technical Outlook: Technically, CSBR is in a downtrend. Immediate support is located at $5.65, while resistance sits at $6.34.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+105.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CSBR is in a downtrend. Immediate support is located at $5.65, while resistance sits at $6.34.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+105.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$5.78 -
$6.07
Company Quality Score
57/100
(HOLD)
Options IV Signal
32th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 32th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 105.5% below Wall St target ($12.00)
- BULLISH: Expecting earnings turnaround to 2.1% growth with -2.8% revenue growth
Fair Price Analysis
30-Day Fair Range
$5.78 -
$6.07
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.79
(13.5%)
Support & Resistance Levels
Support Level
$5.65
Resistance Level
$6.34
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
58.40
Wall Street Target
$12.00
(+105.5%)
Revenue Growth (YoY)
-2.8%
Earnings Growth (YoY)
-61.1%
Profit Margin
-4.0%
Valuation Premium vs History
+2.1% premium
PE vs Historical
58.4 vs 54.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.1%
(market-implied from PE analysis)
1-Year Target
$5.96
(+2%)
2-Year Target
$6.09
(+4%)
3-Year Target
$6.22
(+6%)
3-Yr Target (if PE normalizes)
(PE: 58→55)
PE COMPRESSION
$5.84
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 58.4, Growth: -16.7%)
$4.26
(+-27%)
Base:
(SPY PE: 22.4, Growth: -16.7%)
$1.63
(-72%)
Bear:
(PE: 19.0, Growth: -16.7%)
$1.38
(-76%)
Share & Embed Analysis
Last updated: March 31, 2026 1:30 AM ET
Data refreshes hourly during market hours. Next update: 2:30 AM
Data refreshes hourly during market hours. Next update: 2:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$134 | 59 HOLD |
